Neolaia Bio

What Neolaia Bio does

Neolaia Bio is a pre-clinical biotechnology company developing catalytic small molecule CD38 inhibitors designed to restore NAD+ levels and disrupt inflammation-driven cellular aging. The company's lead development candidate, NEO-1306, is a highly selective, potent molecule engineered for once-daily oral dosing with a wide therapeutic window, and efficacy has been demonstrated across multiple preclinical models. The company targets age-related indications including lung function decline, muscle loss/fatigue, and cognitive decline, with the platform also positioned for applications in immunological disorders, metabolic dysfunction, and weight management.

The underlying technology platform pairs CD38 small molecule chemistry with an AI-enhanced screening capability intended to accelerate drug candidate identification. Neolaia Bio operates a virtual biotech operating model, combining in-house scientific leadership with collaborations across Contract Research Organizations (CROs) and NC Biolabs facilities, which enables efficient capital deployment in the pre-clinical stage. A recently announced partnership with Greenstone Biosciences extends the platform into inflammatory bowel disease (IBD) using iPSC-derived macrophages and human gut organoid models.

The company is privately held, founded in November 2023, and headquartered at 2261 Market Street, STE 5656, San Francisco, California. Neolaia Bio has not disclosed any funding rounds, revenue figures, or commercial products; future revenue is expected to derive from pharmaceutical development and licensing following FDA approval. Its leadership comprises CEO and co-founder Dolca Thomas, M.D., CSO and co-founder J. David Becherer, PhD, and Director of Biochemistry and co-founder Frank Preugschat, PhD. The company cites a potential addressable population of 30 million+ patients and a global market opportunity of up to $30 billion.

Name

Neolaia Bio

Legal name

Neolaia Bio

Website

https://neolaiabio.com

Company type

Private

Founded year

2023

Operating status

Operating

Short description

Neolaia Bio is a pre-clinical biotech developing catalytic small molecule CD38 inhibitors that restore NAD+ levels to treat age-related inflammatory and metabolic conditions, including lung function decline, muscle loss, and cognitive decline, with lead candidate NEO-1306 advancing toward clinical trials.

Ownership category

akta.pro rank

Product category

Small Molecule Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Small molecule therapeutics
• CD38 inhibitors
• NAD+ regulation drugs
• Age-related disease therapeutics
• Anti-aging biopharmaceuticals

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Development and Licensing: Pre-clinical biotech company developing CD38 inhibitors for age-related conditions. Revenue will be generated through drug development成功后可能通过 licensing, partnerships, or commercialization of therapeutic products. Currently in pre-clinical stage with plans to enter clinic by end of year.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Neolaia Bio develops catalytic small molecule CD38 inhibitors that restore NAD+ levels to treat age-related inflammatory and metabolic diseases. Its lead candidate, NEO-1306, is a highly selective, potent, once-daily oral molecule with a wide therapeutic window, demonstrated efficacy in multiple preclinical models, and a strong patent estate, entering the clinic by end of year. The company also advances a broader CD38 Inhibitor Program targeting lung function decline, muscle loss/fatigue, and cognitive decline, supported by an AI-enhanced screening platform.

Product overview

Neolaia Bio is a preclinical biotech company pioneering a pipeline of CD38 inhibitor drugs for age-related diseases. The company's lead development candidate is NEO-1306, a highly selective and potent small molecule designed for once-daily oral dosing that restores NAD+ levels by inhibiting CD38. The broader CD38 Inhibitor Program encompasses catalytic small molecule inhibitors targeting conditions including lung function decline, muscle loss/fatigue, and cognitive decline. The company utilizes an AI-enhanced screening platform for drug candidate identification. The company is entering clinical trials with NEO-1306 by end of year.

Differentiator

Problem solved

Functional benefit

Products and services

• NEO-1306 A highly selective and potent CD38 inhibitor molecule designed for once-daily oral dosing with an excellent safety profile and wide therapeutic window. Demonstrated efficacy across multiple preclinical models, entering clinical trials by end of year. Intended for patients with age-related inflammatory and metabolic conditions.
• CD38 Inhibitor Program

Quantifiable outcome

• Addresses 30M+ patients with up to $30B global market opportunity
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

One partnership is on record.

• Greenstone BiosciencescoreStrategic or Co-development Partner · 19 February 2026Strategic collaboration to advance inflammatory bowel disease (IBD) drug development using iPSC-derived macrophages and patient-relevant human gut organoid models. Under the agreement, Neolaia Bio provides its proprietary drug candidates while Greenstone Biosciences evaluates them using its human-based disease modeling platform designed to recapitulate key inflammatory and epithelial features of IBD. The partnership aims to generate human-based data that better predicts clinical outcomes and reduces drug development risk.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Emerging players

• Altos Labs: Well-funded emerging player focused on cellular rejuvenation programming to restore cell health and reverse age-related disease. Comparable as a high-profile aging therapeutics company, though pursuing different biological approaches (reprogramming vs. CD38 inhibition).
• Life Biosciences: Aging therapeutics company developing multiple programs targeting fundamental mechanisms of aging, including mitochondrial dysfunction and cellular senescence. Comparable through multi-program aging focus, though pursuing different mechanisms.
• Turn Biotechnologies: Emerging aging-focused biotech developing mRNA-based reprogramming technology to restore cell vitality and address age-related conditions. Comparable through aging therapeutic focus and platform-based pipeline strategy, though different modality.
• Calico Life Sciences: Alphabet-backed aging research company developing interventions to address age-related disease and extend human healthspan. Comparable through aging therapeutics focus, with significantly greater resources and broader biological scope.

Direct peers

• Elysium Health: Consumer health company commercializing NAD+ boosting supplements (Basis/NR) targeting cellular aging and longevity. Comparable through NAD+ mechanism, though operating in consumer health rather than prescription drug development.
• BioAge Labs: AI-driven aging biotech developing small molecule therapies for age-related diseases, with a particular focus on muscle biology and metabolic aging. Closely comparable in therapeutic area, modality (small molecules), and AI-enabled discovery approach.
• Unity Biotechnology: Clinical-stage aging biotech developing senolytics and small molecules that target fundamental mechanisms of aging, including inflammation-driven cellular senescence. Comparable as an aging-focused small molecule developer targeting shared inflammaging biology.
• Insilico Medicine: AI-driven drug discovery company with a strong focus on aging and age-related diseases, using generative AI platforms to identify novel small molecule candidates. Comparable through AI-augmented screening and aging therapeutic focus.

Broad incumbents

• Janssen (Johnson & Johnson): Major pharmaceutical company with the leading approved CD38-targeted therapy (daratumumab/Darzalex) for multiple myeloma and other hematologic malignancies. Comparable as the dominant CD38 player with extensive clinical and commercial infrastructure.

Others

• ChromaDex: Supplier of NAD+ precursor ingredients (Niagen/NR) used in supplements and clinical research on aging and longevity. Comparable through shared NAD+ biology focus, though operating as an ingredient supplier rather than a therapeutic developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neolaia Bio